Debiopharm

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.  

Debiopharm currently seeks to strengthen its pipeline of oncology programs focusing on preclinical small molecules and biologics with novel MoAs to treat solid tumor indications. There also is interest in partnering or out-licensing company's proprietary ADC technologies AbYlink and Multilink. 

**Please note we will not accept requests from service providers during this conference**